Taizhou/China and Ingelheim/Germany, 28 August 2008 - Boehringer Ingelheim and Hisoar, a Chinese pharmaceutical production company based in Taizhou, today jointly announced a strategic production alliance in China. Within the the framework of this production alliance Boehringer Ingelheim complements its worldwide chemical production network with strong partners for the manufacturing of chemical intermediates for its active pharmaceutical ingredients (APIs). These chemicals will then be processed further in Boehringer Ingelheim’s plants in Germany, Italy, Spain and the United States.

From September 2008 onwards, Boehringer Ingelheim will supply know-how as well as technical support for production to Hisoar. Hisoar in turn will invest into new specific production facilities for Boehringer Ingelheim at its new site in Chuannan. The production for Boehringer Ingelheim in Chuannan is planned to start in early 2009.

Mr. Bangpeng Luo, the Chairman of Hisoar commented: We are very pleased to have the opportunity to cooperate with Boehringer Ingelheim, a large multinational pharmaceutical company. This cooperation, both from the technical and the management level, will raise Hisoar’s market positioning and standing and it will create an unusual benefit for Hisoar to enter the international levelof raw material suppliers, and indicates that Hisoar has come a big step forward towards internationalization.”

Dr Hans-Jürgen Leuchs, Member of the Board of Managing Directors and responsible for the Corporate Board Division Operations of Boehringer Ingelheim added, “Boehringer Ingelheim is looking forward to a fruitful cooperation with our Chinese partner to have in future more flexibility, short production timelines and an appropriate capacity for the continuously growing demand for Boehringer Ingelheim’s medications across the globe.”

About Hisoar
Established in 1966, Hisoar is a listed company in shenzhen stock exchange market that specializes in the production, sales and distribution of chemical intermediates and active pharmaceutical ingredients to the pharmaceutical industry. It is located in Taizhou of Zhejiang province, one of the areas with the most economic vitality in China. Hisoar is an enterprise which specializes in researching , developing and sales of API, medicine( including high-level intermediate), animal drug and other product in chemical area. In 2007 the sale is RMB 1,035,000,000. Hisoar has Waisha ,Chuannan ,and Quanfeng 3 production bases, the facilities satisfy with the requirement of the pharmaceutical chemistry. Hisoar establishes the GMP and EHS system according the international standard, and several product have passed the COS authentication FDA authentication , PMDA authentication of Europe, America , Japan and other main drug administration market. Hisoar has a certain impact on the area of drug in the international system.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of 10.9 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development.

Please be advised
This release is from the Corporate Headquarters of Boehringer Ingelheim and is intended for all international markets. This being the case, please be aware that there may be some differences between countries regarding specific medical information including licensed uses. Please take account of this when referring to the material.